Spanish dermatology company Almirall (BME: ALM) has provided some detail on the results from a Phase III atopic dermatitis (AD) trial of lebrikizumab.
The results are included in a late-breaking, oral presentation at the annual meeting of the European Academy of Dermatology and Venerology (EADV).
Providing more context to top-line results from the ADvocate 1 and ADvocate 2 trials, the data show long-lasting benefits for people who responded after 16 weeks of treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze